Abstract Number: 947 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of NNC01140006, an Anti-IL-21 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Background/Purpose A phase 2, randomised, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of NNC0114-0006 in patients with active rheumatoid arthritis…Abstract Number: 946 • 2014 ACR/ARHP Annual Meeting
Phase 1 Study of Immunotherapy Using Autoantigen-Loaded Dendritic Cells in Patients with Anti-Citrullinated Peptide Antigen Positive Rheumatoid Arthritis
Background/Purpose To date, no dendritic cell (DC) immunotherapy has been shown to give a benefit in patients with rheumatoid arthritis (RA). In this prospective phase…Abstract Number: 945 • 2014 ACR/ARHP Annual Meeting
Disease Remission Reduces Risk of Heart Failure in Rheumatoid Arthritis Patients Independent of Treatment Strategy
Background/Purpose Risk of heart failure (HF) is increased in patients with RA, however there is great variance in reported prevalence rates due to different diagnostic…Abstract Number: 944 • 2014 ACR/ARHP Annual Meeting
Predict the Chance of Remission for Your RA Patient in Real Life
Background/Purpose: Clinical remission (REM) is the treatment target in rheumatoid arthritis (RA), and there are several composite REM criteria available. Knowledge on how disease duration affects REM…Abstract Number: 943 • 2014 ACR/ARHP Annual Meeting
Improvements in the Proportion of Patients Achieving DAS, CDAI, and SDAI Remission By Omitting the Patient Global Assessment (PtGA): an Analysis from a Prospective, Observational Registry
Background/Purpose: PtGA is included in the formula of all disease activity indices despite the fact that it may not accurately reflect RA disease activity, but…Abstract Number: 942 • 2014 ACR/ARHP Annual Meeting
ACR/EULAR Remission in RA patients in Clinical Practice – Does Substitution of Patient Global with Pain Score Change Remission Rates? Data from the Danish Danbio Registry
Background/Purpose: Modern treatment strategy in RA aims at remission. In 2011, new ACR/EULAR remission criteria were published for patients with RA. Of four Boolean criteria,…Abstract Number: 941 • 2014 ACR/ARHP Annual Meeting
Biologic De-Escalation in Rheumatoid Arthritis: Cost Savings and Clinical Success
Background/Purpose: Economic considerations and clinical risks of prolonged biologic use in Rheumatoid Arthritis (RA) have emerged as concerns. In this study, we measured the clinical…Abstract Number: 940 • 2014 ACR/ARHP Annual Meeting
Reducing Therapy in Rheumatoid Arthritis Patients in Ongoing Remission
Background/Purpose: Due to improved therapeutic management a steadily increasing number of rheumatoid arthritis (RA) patients reach stable remission of disease. Data on withdrawal of medication…Abstract Number: 959 • 2014 ACR/ARHP Annual Meeting
Discoid Lupus Onset and Decrease Risk of Renal Disease in Patients with Systemic Lupus Erythematosus: Data from a Large Latin American Cohort
Background/Purpose .Early data derived from small selected samples suggest that discoid lupus erythematosus (DLE) is negatively associated with renal involvement in patients with SLE. Recent…Abstract Number: 958 • 2014 ACR/ARHP Annual Meeting
The 10-Year Followup of a Trial Comparing Azathioprine and Mycophenolate Mofetil for Long-term Immunosuppression of Lupus Nephritis
Background/Purpose Very longterm data are rarely reported in lupus nephritis (LN) trials, despite their pivotal importance to detect late poor renal outcomers and to identify…Abstract Number: 957 • 2014 ACR/ARHP Annual Meeting
Long-Term Evaluation of NT-Probnp Levels in Ankylosing Spondylitis Patients Under TNF Blockers: A Marker of Persistent Disease Activity?
Background/Purpose N-terminal pro-brain natriuretic peptide (NT-proBNP) is a strong marker of cardiovascular risk with recent evidence that short-term inflammation control reduces its levels in ankylosing…Abstract Number: 956 • 2014 ACR/ARHP Annual Meeting
Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Background/Purpose A definition of minimal disease activity (MDA) in PsA was derived from the opinion of 60 PsA experts including fulfillment of ≥5 of the…Abstract Number: 955 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of a Phase 3, Randomized, Controlled Trial
Background/Purpose Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA).…Abstract Number: 954 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose Approximately two-thirds of patients (pts) with psoriatic arthritis (PsA) experience progressive joint damage associated with varying degrees of disability. Here we present the 1-year…Abstract Number: 927 • 2014 ACR/ARHP Annual Meeting
Urate Crystal Induced Inflammation and Joint Pain Are Reduced in Transient Receptor Potential Ankyrin 1 (TRPA1) Deficient Mice – a New Potential Role for TRPA1 in Gout
Background/Purpose: In the gout, monosodium urate (MSU) crystals deposit intra-articularly and cause painful arthritis. In the present study we tested the hypothesis that Transient Receptor…
ACR Meeting Abstracts